Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Perspective Therapeutics Q2 EPS $(0.30), Inline, Sales $290.000K Beat $154.455K Estimate

Author: Benzinga Newsdesk | August 13, 2025 05:47am
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. This is a 76.47 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $290.000 thousand which beat the analyst consensus estimate of $154.455 thousand by 87.76 percent. This is a 44.87 percent decrease over sales of $526.000 thousand the same period last year.

Posted In: CATX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist